Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Systemic aminocaproic acid showed no clear difference in long‐term visual acuity 20/40 or better > 2 months after treatment compared with placebo (low certainty).
Other pharmaceutical agents showed no clear difference in short‐term visual acuity between 20/20 and 20/60 at end of… compared with placebo or other control interventions (low certainty).
Other pharmaceutical agents showed no clear difference in risk of secondary hemorrhage; conjugated estrogen compared with placebo or other control interventions (moderate certainty).
It is very uncertain whether other pharmaceutical agents changes risk of secondary hemorrhage; cycloplegics compared with placebo or other control interventions (very low certainty).
Other pharmaceutical agents showed no clear difference in risk of secondary hemorrhage; aspirin compared with placebo or other control interventions (low certainty).
Systemic aminocaproic acid showed no clear difference in final visual acuity 20/40 or better at resolution of hyphema compared with placebo (low certainty).
Systemic aminocaproic acid may leads to lower secondary hemorrhage at any time point compared with placebo (low certainty).
Systemic aminocaproic acid probably leads to higher adverse effects: nausea or vomiting compared with placebo (moderate certainty).
Topical aminocaproic acid showed no clear difference in short‐term visual acuity 20/40 or better ≤ 2 weeks after treatment compared with placebo (low certainty).
The review found no eligible studies for this question.
Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in death or dependence (mRS 4–6) compared with placebo/open control (low certainty).
Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in all serious adverse events compared with placebo/open control (high certainty).
Summary of findings table ‐ Antifibrinolytic drug(s) showed no clear difference in death from any cause compared with placebo/open control (high certainty).
Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in intracerebral haemorrhage expansion by 24 hours compared with placebo/open control (low certainty).
It is very uncertain whether summary of findings table ‐ Recombinant activated factor VII changes all serious adverse events compared with placebo/open control (very low certainty).
Summary of findings table ‐ Recombinant activated factor VII showed no clear difference in death from any cause compared with placebo/open control (moderate certainty).